Tibulizumab

Names

[ Name ]:
Tibulizumab

Biological Activity

[Description]:

Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research[1].

[Related Catalog]:

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

Research Areas >> Inflammation/Immunology

[Target]

IL-17A:14 pM (Kd)

BAFF:60 pM (Kd)

[In Vitro]

Tibulizumab (LY 3090106) 与小鼠 BAFF 结合，KD 为 340 nM，但不与小鼠 IL-17 结合。Tibulizumab 与猕猴 BAFF 和猕猴 IL-17 结合，KD 分别为 26.8 pM 和 19 pM[1]。在 HT-29 细胞中，Tibulizumab 以浓度依赖性方式拮抗 IL-17 诱导的 CXCL1 分泌 (IC50 为 2.00 nM)。在 T1165 细胞中，Tibulizumab 以浓度依赖性方式阻断 BAFF 诱导的增殖 (IC50 为 0.064 nM)。Tibulizumab 同时结合并阻断 BAFF 和 IL-17[1]。

[In Vivo]

Tibulizumab（LY 3090106；660 µg/小鼠，i.p；66 µg/小鼠，s.c）在小鼠体内有效拮抗人 BAFF 和 IL-17 诱导的生物学效应[1]。在食蟹猴中，Tibulizumab（i.v，0.3、1、5 或 20 mg/kg；或 s.c，5 mg/kg）抑制 B 细胞发育和存活，并在循环中保持功能完整，并延长半衰期 [1]。

[References]

[1]. Robert J Benschop, et al. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. MAbs. 2019 Aug/Sep;11(6):1175-1190.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.